secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2026-08-06T11:35:16+00:00
Accession:  0001193125-26-336762
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio Q2 2026 cash $239.2M; pipeline advances with CLYM116 Phase 2 initiation in Q3
--------------------------------------------------------------------------------

- Cash, cash equivalents, and marketable securities $239.2M as of June 30, 2026; raised ~$110M in private placement in April 2026, extending runway into H2 2028.
- R&D expenses $9.7M (vs $6.6M YoY); G&A $5.6M (vs $4.1M YoY); other income $1.9M.
- CLYM116 Phase 1 data to be presented at R&D Spotlight on Sept 3, 2026; Phase 2 trial in IgAN to start dosing in Q3 2026.
- Budoprutug data expected from pMN, ITP, and SLE studies in Q4 2026; SC formulation data positive.
- Appointed Breanna O'Reilly, Ph.D., to Board of Directors in June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526336762/0001193125-26-336762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526336762/clym-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-336762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer